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The elderly is characterised by loss of functional reserve, loss
of independence in activity of daily living, loss in social support.2
In the elderly population we can observe person who are like
younger people (fit elderly) and people who are clearly weak (frail
elderly) but there is a lot of intermediate cases more difficult to
evaluate.3 If in younger people survival is the most important out-
come in older persons often quality of life and symptommanage-
ment are the first.4
To obtain a new prognostic therapeutic Index to use in clinical
practice in geriatric oncology we evaluated 54 older cancer
patients (25 women, 29 men), age 72 ± 5 receiving chemo by
ADL), IADL, social and economic support, handgrip, walking and
standing up from a chair velocity, gait balance performance
(standing balance, semi-tandem, tandem), Mini Mental state
examination, Geriatric Depression Scale short form, CIRS-G Tinet-
ti’s test, Mini Nutritional Assessment, FACT, VAS for pain and QoL,
Caregiver Burden Inventory (CBI). Then we applied to results the
polar diagram5 and obtained a numerical index, correlated to
overall survival.
Regard to total cancer population we did not obtain significant
correlation with our index and survival. However, when we con-
sidered the two most frequent diagnosis, colon cancer and lung
cancer (NSCLC) we achieved an interesting relationship which
have not statistical significance for the small population
considered.
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The Comprehensive Geriatric Assessment in Oncology is now
usually considered the instrument to evaluate elderly cancer
patients, but there is no clear model for practical use of geriatric
instruments. We are working to obtain a useful prognostic-thera-
peutic index ease to use in clinical practice.
doi:10.1016/j.ejcsup.2008.06.056
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Background: The estimated incidence rates for all cancers in
Europeanmen andwomen is 2.9  100,000 in the 70 years or more
group and 2.2  100,000 in the 55–64 age group. Given the great
importance of elderly population in cancer, it is interesting to
assess their management with modern chemotherapeutic regi-
mens considering tollerability and toxicity. Because elderly
patients are frequently excluded from randomized trials, data
regarding toxicity and tollerabilty are lacking.
Aims: To assess incidence of toxicity complications in this set-
ting of patients.
Patients and methods: From October 2004 to March 2008 a total
of 30 cancer (12 left colon, 6 right colon, 6 rectal and 6 gastric)
patients older than 70 years, treated with Folfox regimen, were
evaluated for chemotherapy-related toxicity. Median age was 71
(range 70–80), 24 (80%) were treated with Folfox4 regimen and 6
(20%) with Folfox6. 26 (87%) patients were stage IV colon and gas-
tric cancer and 4 (12%) were stage III colon cancer. In stage IV can-
cer, 22 (73%) patient underwent Folfox regimen as first line
chemotherapy, 3 as second line and 1 as third line. Toxicity was
evaluated according by NCI-CTC version 2.0.
Results: A total of 146 cycles were administered; 16 (54%)
patients completed 6 cycles of Folfox, 14 (46%) stopped Folfox
administration for PD. The most common comorbidity was hyper-
tensions (17 patients 57%), 5 (16.6%) had no comorbidities. Grades
3 and 4 toxicity occurred in 73% of patients. The main toxicities
was neutropenia, observed in 64% of patients (afebrile grade 4
in 3 (10%) patients, grade 3 in 6 (20%) patients); sensory neurotox-
icity occurred in 70% patients (6 (20%) grade 3 and 15 (50%)
grade 2). Grade 3 diarrhoea occurred in 4 (13.3%) patients, 15
(50%) had grade 2 diarrhoea. 3 (10%) patients had grade 3 mucosi-
tis and 11 (36.6%) had grade 2. Two patients developed atrial flut-
ter but hearth rate and sinus rhythm were restored with
medication. No grade 4 neurotoxicity, diarrhoea and mucositis
was observed.
Conclusion: In our results therapeutic compliance of patients
aged >70 was good. Elderly patients experienced only slightly
more toxicity than younger patients in the two most common
side effects of Folfox: neutropenia and sensory neuropathy.
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